Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 save search
Biohaven Presents New Migraine Data at 64th Annual Scientific Meeting of the American Headache Society, including First of Its Kind Study for Nurtec® ODT (rimegepant), and Complete Phase 3 Data for Zavegepant Nasal Spray
Published: 2022-06-13 (Crawled : 12:00) - prnewswire.com
BHVN 1 d | $38.99 -7.52% 0.0% 3.4M
|
Health Technology
|
| O: -0.41%
H: 0.44%
C: 0.14%
nurtec migraine phase 3
Endo Executes Agreement With TLC to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain
Published: 2022-06-13 (Crawled : 11:00) - prnewswire.com
ENDP | $0.2926 -9.6%
|
Health Technology
|
| O: 5.35%
H: 1.26%
C: -21.85%
treatment osteoarthritis phase 3
Oncternal Therapeutics Presents Rationale and Plans for its Registrational Phase 3 Study Evaluating Zilovertamab in Combination with Ibrutinib at the EHA 2022 Congress
Published: 2022-06-10 (Crawled : 13:20) - globenewswire.com
ONCT | $8.97 4.3% 4.12% 4.5K
|
Health Technology
|
| O: -5.67%
H: 0.0%
C: 0.0%
therapeutics phase 3
Biohaven Underscores Depth of Migraine Portfolio with Data from Nurtec® ODT (rimegepant) Long-Term Open Label Study and Phase 3 Zavegepant Trial at 64th Annual Scientific Meeting of the American Headache Society
Published: 2022-06-09 (Crawled : 13:00) - biospace.com/
BHVN 1 d | $38.99 -7.52% 0.0% 3.4M
|
Health Technology
|
| O: -0.08%
H: 0.25%
C: -0.26%
nurtec label trial migraine phase 3
BridgeBio Pharma to Present Phase 2b Data and Pivotal Phase 3 Study Design of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) at the Endocrine Society (ENDO) 2022 Annual Conference
Published: 2022-06-09 (Crawled : 13:00) - biospace.com/
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: -7.3%
H: 0.0%
C: 0.0%
pharma conference endocrine phase 3 phase 2b
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPDTop-line data expected from ENHANCE-2 in Q3 2022 and ENHANCE-1 around the end of 2022
Published: 2022-06-09 (Crawled : 10:00) - biospace.com/
VRNA | $15.82 -1.74% -1.83% 640K
|
Health Technology
|
| O: 2.05%
H: 0.6%
C: -13.68%
treatment pharma expected trial phase 3
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
Published: 2022-06-09 (Crawled : 07:00) - globenewswire.com
VRNA | $15.82 -1.74% -1.83% 640K
|
Health Technology
|
| O: 2.05%
H: 0.6%
C: -13.68%
treatment pharma trial phase 3
FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy
Published: 2022-06-08 (Crawled : 16:00) - biospace.com/
FGEN | $1.15 -1.71% -1.74% 1.3M
|
Health Technology
|
| O: -1.43%
H: 3.38%
C: -0.39%
duchenne phase 3
Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022
Published: 2022-06-08 (Crawled : 15:20) - biospace.com/
AMYT | $14.7 0.0% 2.4M
|
Health Technology
|
| O: 0.0%
H: 1.65%
C: -0.89%
mycapssa trials label phase 3
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY‑2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease
Published: 2022-06-08 (Crawled : 13:00) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: 21.45%
H: 0.0%
C: 0.0%
drug disease eye application trial therapeutics phase 3
Marinus Pharmaceuticals Expands Enrollment Criteria to Support Recruitment in Phase 3 RAISE Trial in Refractory Status Epilepticus
Published: 2022-06-08 (Crawled : 12:20) - biospace.com/
MRNS | $1.38 -2.13% -2.17% 2.6M
|
Health Technology
|
| O: 5.6%
H: 3.53%
C: -0.71%
epilepticus trial phase 3
Rigel Announces Top-line Results from FORWARD Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune Hemolytic Anemia
Published: 2022-06-08 (Crawled : 12:20) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 3.02%
H: 0.98%
C: 0.34%
RIGL | $1.07 1.91% 1.87% 810K
|
Health Technology
|
| O: -45.22%
H: 9.28%
C: -21.07%
anemia trial results topline phase 3
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease
Published: 2022-06-07 (Crawled : 21:00) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: -1.25%
H: 0.0%
C: 0.0%
conference disease eye trial therapeutics results topline phase 3
DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers
Published: 2022-06-07 (Crawled : 21:00) - globenewswire.com
DBVT | $0.671 1.51% 1.49% 39K
|
Health Technology
|
| O: 19.61%
H: 0.0%
C: 0.0%
topline trial positive results phase 3
CEL-SCI Presents Phase 3 Multikine Head & Neck Cancer Data at ASCO
Published: 2022-06-07 (Crawled : 13:00) - biospace.com/
CVM | $1.56 4.0% 0.0% 230K
|
Health Technology
|
| O: -11.26%
H: 14.2%
C: 12.39%
asco cancer phase 3
Apellis and Sobi Announce First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need
Published: 2022-06-07 (Crawled : 12:20) - biospace.com/
PPRUF | $358.55 37.56% 1.5K
|
Consumer Non-Durables
|
| O: 3.52%
H: 1.44%
C: -2.89%
PPRUY | $36.0023 -0.11% 220K
|
Manufacturing
|
| O: -1.18%
H: 1.95%
C: 1.75%
APLS G | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: -7.87%
H: 5.53%
C: 5.37%
rare kidney phase 3
Moderna Announces First Participants Dosed in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010)
Published: 2022-06-07 (Crawled : 12:00) - biospace.com/
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: 0.63%
H: 0.0%
C: 0.0%
rna-1010 vaccine influenza phase 3
Merck and Ridgeback Announce New Data For Investigational LAGEVRIO™ (molnupiravir) From Phase 3 MOVe-OUT Study
Published: 2022-06-07 (Crawled : 12:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
| Email alert
Add to watchlist
phase 3
Final Data From Phase 3 ASCENT Study Demonstrates Trodelvy Extends Overall Survival Over Chemotherapy in Second-Line Metastatic TNBC
Published: 2022-06-06 (Crawled : 15:20) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -1.24%
H: 0.71%
C: -0.87%
trodelvy phase 3
Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2022-06-06 (Crawled : 13:00) - ir.radiuspharm.com
RDUS | $18.41 -0.61% -0.61% 220K
|
Health Technology
|
| O: 1.01%
H: 4.6%
C: 0.92%
elacestrant trial group phase 3 elascestrant
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.